Novocure: Microwave News Article Archive (2004 - )
Supplementing chemotherapy with 200 kHz E-fields increased progression-free survival (by 2.7 months to 6.7 months) and overall survival (by 4.9 months to 20.9 months) in patients with newly diagnosed glioblastoma. Both are statistically significant improvements.
Novocure’s 200 kHz signals kept 43% of GBM patients alive compared to 30% on the standard treatment.
For more on Novocure, going back to 2007, follow this link.
The latest on NovoCure’s EM therapy for brain tumors. Not a cure; it increases overall survival time by about three months. The cost is high: $21,000/month. See also our other stories about NovoCure going back to 2007.
“I am the happiest man alive,” says Robert Dill-Bundi, the Swiss Olympic cycling champion. Dill-Bundi developed a glioblastoma multiforme, an aggressive, usually fatal, type of brain tumor, but is still alive years after being treated with electric fields. The therapy was developed by Novocure, an Israeli company (see: ...
A system to treat brain cancer with 100-200 kHz electric fields has been approved by the FDA. The device is made by Novocure. Here is the company's press release announcing the news. And here is a link to a story about the the device, we ran in Microwave News close to four years ago.
